Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Out of 538 articles, 23 (4.27%) were published in journals from the geriatric category, 44 (8.18%) included an author affiliated with a geriatric institution.
-
Recently, the U.S. Food and Drug Administration (FDA) approved 2 anti-amyloid monoclonal antibodies, aducanumab (June 7, 2021) and lecanemab (July 6, 2023), for the treatment of Alzheimer's disease (AD) patients, and will most likely also approve a 3rd one, donanemab, soon.
-
Crude AD prevalence (2015-2020) was estimated at 760.5 per 100,000 inhabitants, and age-standardized prevalence (2020) was 664.6 (male 595.7, female 711.0).
-
The plasma p-tau217 and plasma GFAP models adequately predicted the change over time, with donanemab resulting in decreased plasma p-tau217 and plasma GFAP concentrations.
-
45/100
Hardy and Mummery discuss the recent positive findings in the clinical trial of lecanemab in early Alzheimer’s disease, and the implications for the amyloid hypothesis.
-
Donanemab is an amyloid-targeting therapy that resulted in robust amyloid plaque reduction and slowed Alzheimer's disease (AD) progression compared with placebo in the phase II TRAILBLAZER-ALZ study (NCT03367403).
-
45/100
With the recent approval by the FDA of the first disease-modifying drug for Alzheimer's Disease (AD), personalized medicine will be increasingly important for appropriate management and counseling of patients with AD and those at risk.
-
Third, in many cases, Susac syndrome is diagnosed and treated late, with significant irreversible sequelae including dementia, blindness and hearing loss.
-
The calibrated model predicts that endogenous plaque turnover is slow, with an estimated half-life of 2.75 years.
-
45/100
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations.
-
Drug development for Alzheimer disease and other neurodegenerative dementias, including frontotemporal dementia, has experienced a long history of phase 2 and phase 3 clinical trials that failed to show efficacy of investigational drugs.
-
45/100
There was strong evidence of a causal association between glioma risk, reduced trunk fat-free mass, lower education levels, lower intelligence and a higher risk of AD.
-
Drug development continues robustly at all phases despite setbacks in several programs in the recent past.
-
45/100
A group of European experts was commissioned by the European Chapter of the International Federation of Clinical Neurophysiology to gather knowledge about the state of the art of the therapeutic use of transcranial direct current stimulation (tDCS) from studies published up until September 2016, regarding pain, Parkinson's disease, other movement disorders, motor stroke, poststroke aphasia, multiple sclerosis, epilepsy, consciousness disorders, Alzheimer's disease, tinnitus, depression, schizophrenia, and craving/addiction.
-
The purpose of the study was to evaluate the influences of cholinesterase inhibitors on sleep pattern and sleep disturbance.
-
The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores and Hasegawa dementia rating for 6 months, and then significantly declined at 12 months in both subgroups.
-
Patients completed a survey assessing statin-associated, cognitive-specific adverse drug reaction (ADR) characteristics, relation of the ADR to specific statin and dose (or potency), and time course of symptom onset and recovery.
-
45/100
Patients on donepezil showed selective and significant (p<0.05) improvement on the memory subscale of the Dementia Rating Scale.
-
Behavioural troubles due to frontotemporal dementia (FTD) are difficult to treat.
-
Recipients of galantamine 16 or 24 mg/day achieved significant improvements in cognitive and global symptoms relative to placebo recipients in large (n = 285 to 978 patients with mild to moderate AD) well-designed trials of 3 to 6 months' duration.
-
Galantamine appears to be an effective and safe therapy for patients with DLB.
-
Prevention of Alzheimer disease (AD) is a medical challenge owing to its complex pathogenesis, which involves amyloid-β (Aβ) and tau aggregation, neuroinflammation and progressive neurodegeneration.
-
Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the accumulation of amyloid-beta (Aβ) in the walls of cerebral vessels.
-
A recent phase III trial testing exendin-4 did not show an improvement, which may be linked to the lack of insulin desensitization in the study participants.
-
43/100
We retrospectively reviewed 20 consecutive patients with Alzheimer's disease who switched from lecanemab to donanemab.
From across this topic
10 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
- Alzheimer's disease: treatments in discovery and development
- Viewpoint: Clinicians' Perspectives on How Disease Modifying Drugs for Alzheimer's Disease Impact Specialty Care
- Safety and efficacy of galantamine in subjects with mild cognitive impairment
- Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease
- Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials
- Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study
- Pharmacological Approaches Using Diabetic Drugs Repurposed for Alzheimer's Disease
- Consumption of drugs for Alzheimer's disease on the Brazilian private market
- Sleep disturbances in patients with Alzheimer's disease: epidemiology, pathophysiology and treatment